The validation of an in vitro colonic motility assay as a biomarker for gastrointestinal adverse drug reactions

Toxicology and Applied Pharmacology

Volumn 245, Issue 3, 2010, Pages 299-309

  Keating, Christopher ^a   Martinez, Vicente ^b,c   Ewart, Lorna ^b   Gibbons, Stephen ^a,d   Grundy, Luke ^a   Valentin, Jean Pierre ^b   Grundy, David ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Adverse drug reactions; Biomarkers; Colonic motility; Gastrointestinal tract; Safety assessment

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; BACLOFEN; BIOLOGICAL MARKER; CARBACHOL; CLONIDINE; DILTIAZEM; ERYTHROMYCIN; GRANISETRON; LOPERAMIDE; N(G) NITROARGININE METHYL ESTER; NEOSTIGMINE; OCTREOTIDE; SOTALOL; TEGASEROD;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLON MOTILITY; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DETERMINATION; DRUG SAFETY; GASTROINTESTINAL TOXICITY; IN VITRO STUDY; INTESTINE CONTRACTION; INTESTINE PRESSURE; MALE; MOUSE; NONHUMAN; PREDICTION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ANIMALS; COLON; CONSTIPATION; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; MALE; MICE; MICE, INBRED C57BL; PERISTALSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TOXICITY TESTS;

EID: 77952953522     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.03.014     Document Type: Article

References (49)

1. Abdu F., Hicks G.A., Hennig G., Allen J.P., Grundy D. Somatostatin sst(2) receptors inhibit peristalsis in the rat and mouse jejunum. Am. J. Physiol Gastrointest. Liver Physiol. 2002, 282:G624-G633.
2. Anderson J.L., Prystowsky E.N. Sotalol: An important new antiarrhythmic. Am. Heart J. 1999, 137:388-409.
3. Aoki F.Y., Sitar D.S. Clinical pharmacokinetics of amantadine hydrochloride. Clin. Pharmacokinet. 1988, 14:35-51.
4. Beattie D.T., Smith J.A., Marquess D., Vickery R.G., Armstrong S.R., Pulido-Rios T., McCullough J.L., Sandlund C., Richardson C., Mai N., Humphrey P.P. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol. 2004, 143:549-560.
5. Brookes S.J., Chen B.N., Costa M., Humphreys C.M. Initiation of peristalsis by circumferential stretch of flat sheets of guinea-pig ileum. J. Physiol 1999, 516(Pt 2):525-538.
6. Catnach S.M., Fairclough P.D. Erythromycin and the gut. Gut 1992, 33:397-401.
7. Cellek S., Thangiah R., Bassil A.K., Campbell C.A., Gray K.M., Stretton J.L., Lalude O., Vivekanandan S., Wheeldon A., Winchester W.J., Sanger G.J., Schemann M., Lee K. Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. Gastroenterology 2007, 133:175-183.
8. Chassany O., Michaux A., Bergmann J.F. Drug-induced diarrhoea. Drug Saf. 2000, 22:53-72.
9. Chiba T., Thomforde G.M., Kost L.J., Allen R.G., Phillips S.F. Motilides accelerate regional gastrointestinal transit in the dog. Aliment. Pharmacol. Ther. 2000, 14:955-960.
10. Coupar I.M., Liu L. A simple method for measuring the effects of drugs on intestinal longitudinal and circular muscle. J. Pharmacol. Toxicol. Methods 1996, 36:147-154.
11. Crowell M.D., Mathis C., Schettler V.A., Yunus T., Lacy B.E. The effects of tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes mellitus. Neurogastroenterol. Motil. 2005, 17:738-743.
12. DrugDexs Drug Knowledges System 2007, Thomson Micromedex.
13. Fung M. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Inf. J. 2001, 35:293-317.
14. Genschow E., Spielmann H., Scholz G., Seiler A., Brown N., Piersma A., Brady M., Clemann N., Huuskonen H., Paillard F., Bremer S., Becker K. The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Altern. Lab. Anim. 2002, 30:151-176.
15. Gremlich H.U., Martinez V., Kneuer R., Kinzy W., Weber E., Pfannkuche H.J., Rudin M. Noninvasive assessment of gastric emptying by near-infrared fluorescence reflectance imaging in mice: pharmacological validation with tegaserod, cisapride, and clonidine. Mol. Imaging 2004, 3:303-311.
16. Hanauer S.B. The role of loperamide in gastrointestinal disorders. Rev. Gastroenterol. Disord. 2008, 8:15-20.
17. Harrison A.P., Erlwanger K.H., Elbrond V.S., Andersen N.K., Unmack M.A. Gastrointestinal-tract models and techniques for use in safety pharmacology. J. Pharmacol. Toxicol. Methods 2004, 49:187-199.
18. Henry D.A., Ostapowicz G., Robertson J. Drugs as a cause of gastrointestinal disease. Baillieres Clin. Gastroenterol. 1994, 8:271-300.
19. Herbert M.K., Weis R., Holzer P., Roewer N. Peristalsis in the Guinea pig small intestine in vitro is impaired by acetaminophen but not aspirin and dipyrone. Anesth. Analg. 2005, 100:120-127.
20. Heron J.F., Goedhals L., Jordaan J.P., Cunningham J., Cedar E. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. Ann. Oncol. 1994, 5:579.
21. Kishibayashi N., Tomaru A., Ichikawa S., Kitazawa T., Shuto K., Ishii A., Karasawa A. Enhancement by KW-5092, a novel gastroprokinetic agent, of the gastrointestinal motor activity in dogs. Jpn. J. Pharmacol. 1994, 65:131-142.
22. Kraichely R.E., Strege P.R., Sarr M.G., Kendrick M.L., Farrugia G. Lysophosphatidyl choline modulates mechanosensitive L-type Ca2+ current in circular smooth muscle cells from human jejunum. Am. J. Physiol Gastrointest. Liver Physiol. 2009, 296:G833-G839.
23. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 2005, 22:731-740.
24. Leong R.W., Chan F.K. Drug-induced side effects affecting the gastrointestinal tract. Expert. Opin. Drug Saf. 2006, 5:585-592.
25. Lewis J.H. Gastrointestinal injury due to medicinal agents. Am. J. Gastroenterol. 1986, 81:819-834.
26. Makins R., Ballinger A. Gastrointestinal side effects of drugs. Expert. Opin. Drug Saf. 2003, 2:421-429.
27. Mittelstadt S.W., Hemenway C.L., Spruell R.D. Effects of fasting on evaluation of gastrointestinal transit with charcoal meal. J. Pharmacol. Toxicol. Methods 2005, 52:154-158.
28. Neal K.B., Parry L.J., Bornstein J.C. Strain-specific genetics, anatomy and function of enteric neural serotonergic pathways in inbred mice. J. Physiol 2009, 587:567-586.
29. Osinski M.A., Seifert T.R., Cox B.F., Gintant G.A. An improved method of evaluation of drug-evoked changes in gastric emptying in mice. J. Pharmacol. Toxicol. Methods 2002, 47:115-120.
30. Otterson M.F., Sarna S.K. Gastrointestinal motor effects of erythromycin. Am. J. Physiol. 1990, 259:G355-G363.
31. Peck R.W. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. Drug Discov. Today 2007, 12:289-294.
32. Peeters T., Matthijs G., Depoortere I., Cachet T., Hoogmartens J., Vantrappen G. Erythromycin is a motilin receptor agonist. Am. J. Physiol. 1989, 257:G470-G474.
33. Redfern W.S., Wakefield I.D., Prior H., Pollard C.E., Hammond T.G., Valentin J.P. Safety pharmacology-a progressive approach. Fundam. Clin. Pharmacol. 2002, 16:161-173.
34. Reis J., John D., Heimeroth A., Mueller H.H., Oertel W.H., Arndt T., Rosenow F. Modulation of human motor cortex excitability by single doses of amantadine. Neuropsychopharmacology 2006, 31:2758-2766.
35. Rodriguez-Membrilla A., Martinez V., Jimenez M., Gonalons E., Vergara P. Is nitric oxide the final mediator regulating the migrating myoelectric complex cycle?. Am. J. Physiol. 1995, 268:G207-G214.
36. Sanger G.J., Wardle K.A. Constipation evoked by 5-HT3-receptor antagonism: evidence for heterogeneous efficacy among different antagonists in guinea-pigs. J. Pharm. Pharmacol. 1994, 46:666-670.
37. Scarpignato C., Pelosini I. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Can. J. Gastroenterol. 1999, 13 Suppl A:50A-65A.
38. Seiler R., Rickenbacher A., Shaw S., Haefliger S., Balsiger B.M. Role of selective alpha and beta adrenergic receptor mechanisms in rat jejunal longitudinal muscle contractility. J. Gastrointest. Surg. 2008, 12:1087-1093.
39. Striessnig J., Grabner M., Mitterdorfer J., Hering S., Sinnegger M.J., Glossmann H. Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol. Sci. 1998, 19:108-115.
40. Takahashi A., Tomomasa T., Kaneko H., Hatori R., Ishige T., Suzuki M., Mochiki E., Morikawa A., Kuwano H. In vivo recording of colonic motility in conscious rats with deficiency of interstitial cells of Cajal, with special reference to the effects of nitric oxide on colonic motility. J. Gastroenterol. 2005, 40:1043-1048.
41. Valentin J.P., Bialecki R., Ewart L., Hammond T., Leishmann D., Lindgren S., Martinez V., Pollard C., Redfern W., Wallis R. A framework to assess the translation of safety pharmacology data to humans. J. Pharmacol. Toxicol. Methods. 2009, 60:152-158.
42. Valentin J.P., Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J. Pharmacol. Toxicol. Methods 2008, 58:77-87.
43. Veysey M.J., Thomas L.A., Mallet A.I., Jenkins P.J., Besser G.M., Wass J.A., Murphy G.M., Dowling R.H. Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones. Gut 1999, 44:675-681.
44. Wagstaff A.J., Frampton J.E., Croom K.F. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs 2003, 63:1101-1120.
45. Wakefield I.D., Pollard C., Redfern W.S., Hammond T.G., Valentin J.P. The application of in vitro methods to safety pharmacology. Fundam. Clin. Pharmacol. 2002, 16:209-218.
46. Waterman S.A., Costa M. The role of enteric inhibitory motoneurons in peristalsis in the isolated guinea-pig small intestine. J. Physiol 1994, 477(Pt 3):459-468.
47. Wegener J.W., Schulla V., Lee T.S., Koller A., Feil S., Feil R., Kleppisch T., Klugbauer N., Moosmang S., Welling A., Hofmann F. An essential role of Cav1. 2L-type calcium channel for urinary bladder function. FASEB J. 2004, 18:1159-1161.
48. Zanetti L.A. Sotalol: a new class III antiarrhythmic agent. Clin. Pharm. 1993, 12:883-891.
49. Zhang L.B., Horowitz B., Buxton I.L. Muscarinic receptors in canine colonic circular smooth muscle: I. Coexistence of M2 and M3 subtypes. Mol. Pharmacol. 1991, 40:943-951.